Haemonetics (HAE) revenue
Haemonetics (HAE) reported revenue of $1.33B in fiscal 2026 (the year ended March 31, 2026). That is 2.0% lower than the $1.36B of fiscal 2025. Figures as of 18 Nov 2026, 09:05 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2026
- $1.33B
- Change on fiscal 2025
- −2.0%
- Growth, 5 years
- +8.9% a year
- Growth, 10 years
- +3.9% a year
- Highest on record
- $1.36Bfiscal 2025
- Lowest on record
- $597.88Mfiscal 2009
- Fiscal years on record
- 182009–2026
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Haemonetics revenue, in more detail
Over the five fiscal years to 2026 revenue grew at a compound 8.9% a year; over ten years the rate was 3.9% a year. Across the 18 fiscal years on record (2009–2026), the highest was $1.36B in fiscal 2025 and the lowest $597.88M in fiscal 2009.
Revenue by fiscal year
Haemonetics revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2026 | $1.33B | 2.0% down | |
| 2025 | $1.36B | 4.0% up | |
| 2024 | $1.31B | 12.0% up | |
| 2023 | $1.17B | 17.7% up | |
| 2022 | $993.20M | 14.1% up | |
| 2021 | $870.46M | 11.9% down | |
| 2020 | $988.48M | 2.2% up | |
| 2019 | $967.58M | 7.0% up | |
| 2018 | $903.92M | 2.0% up | |
| 2017 | $886.12M | 2.5% down | |
| 2016 | $908.83M | 0.2% down | |
| 2015 | $910.37M | 3.0% down | |
| 2014 | $938.51M | 5.2% up | |
| 2013 | $891.99M | 22.6% up | |
| 2012 | $727.84M | 7.6% up | |
| 2011 | $676.69M | 4.8% up | |
| 2010 | $645.43M | 8.0% up | |
| 2009 | $597.88M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Revenue at health care companies of similar size
| Company | Revenue | Fiscal year |
|---|---|---|
| Hims & Hers Health HIMS | $2.35B | 2025 |
| PTC Therapeutics PTCT | $1.73B | 2025 |
| Haemonetics HAE | $1.33B | 2026 |
| Concentra Group Holdings Parent CON | $2.16B | 2025 |
| Merit Medical Systems MMSI | $1.52B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Haemonetics, figure by figure
- Haemonetics market cap
- Haemonetics earnings
- Haemonetics earnings per share (EPS)
- Haemonetics P/E ratio
- Haemonetics P/S ratio
- Haemonetics P/B ratio
- Haemonetics free cash flow
- Haemonetics operating margin
- Haemonetics dividend
- Haemonetics shares outstanding
- Haemonetics total debt
- Haemonetics cash on hand
- Haemonetics total assets
- Haemonetics return on equity (ROE)
- Haemonetics return on invested capital (ROIC)
Haemonetics (HAE) overview: price, valuation and scorecardAll health care companies by market value
Haemonetics revenue: questions and answers
What is Haemonetics's revenue?
Haemonetics (HAE) reported revenue of $1.33B in fiscal 2026 (the year ended March 31, 2026). That is 2.0% lower than the $1.36B of fiscal 2025.
What is the growth rate of Haemonetics's revenue?
Over the five fiscal years to 2026 revenue grew at a compound 8.9% a year; over ten years the rate was 3.9% a year.
What are the highest and lowest revenue figures on record for Haemonetics?
Across the 18 fiscal years on record (2009–2026), the highest was $1.36B in fiscal 2025 and the lowest $597.88M in fiscal 2009.
How is Haemonetics's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Haemonetics it is on record here for 18 fiscal years, 2009 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Haemonetics (HAE) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/HAE/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.